Trifluoroacetic acid → Mivavotinib

HRID 516000Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 516000
[F:1][C:2]1[C:3]2[CH2:31][NH:30][C:29](=[O:32])[C:4]=2[C:5]([C:23]2[CH:24]=[N:25][N:26]([CH3:28])[CH:27]=2)=[N:6][C:7]=1[NH:8][C@@H:9]1[CH2:14][CH2:13][CH2:12][CH2:11][C@@H:10]1[NH:15]C(=O)OC(C)(C)C.[C:33]([OH:39])([C:35]([F:38])([F:37])[F:36])=[O:34]>C(Cl)Cl>[C:33]([OH:39])([C:35]([F:38])([F:37])[F:36])=[O:34].[NH2:15][C@H:10]1[CH2:11][CH2:12][CH2:13][CH2:14][C@H:9]1[NH:8][C:7]1[N:6]=[C:5]([C:23]2[CH:24]=[N:25][N:26]([CH3:28])[CH:27]=2)[C:4]2[C:29](=[O:32])[NH:30][CH2:31][C:3]=2[C:2]=1[F:1]

Komponenten

5

Versuchsvorschrift

A solution of tert-butyl (1S,2R)-2-(7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (15 mg, 0.034 mmol) and TFA (0.5 mL, 6.49 mmol) in DCM (0.5 mL) was stirred at RT for 30 min. The reaction mixture was concentrated and the resulting residue was purified by preparative HPLC to give a TFA salt of the title compound (7 mg, 60.2%). 1H NMR (500 MHz, DMSO-d6) δ ppm 1.37-2.01 (m, 8 H), 3.67 (br s, 1 H), 3.89 (s, 3 H), 4.32-4.43 (m, 2 H), 4.45 (br s, 1 H), 6.77 (d, J=6.35 Hz, 1 H), 7.93 (br s, 3 H), 8.30 (s, 1 H), 8.36 (s, 1 H), 8.84 (s, 1 H). [M+H] calc'd for C17H21FN6O, 345; found, 345.

Aufarbeitung

  1. concentrationThe reaction mixture was concentrated
  2. customthe resulting residue was purified by preparative HPLC

Quellen und Nachweise

ORD-Eintrag
ord-fc4809769d624734aaf202fd3f44b453
Quelldatensatz
uspto-grants-2015_08
Patentnummer
US09108970B2

Notizen zur Reaktion

Wird geladen…